Evoke Pharma Q4 2023 GAAP EPS $(0.59) Misses $(0.50) Estimate, Sales $1.676M Beat $1.632M Estimate

Evoke Pharma (NASDAQ:EVOK) reported quarterly losses of $(0.59) per share which missed the analyst consensus estimate of $(0.50) by 18 percent. The company reported quarterly sales of $1.676 million which beat the analyst consensus estimate of $1.632 million by 2.70 percent. This is a 110.55 percent increase over sales of $796.000 thousand the same period last year.